These findings suggested that GFAP might reflect astrocytic activation and disease burden in pediatric-onset disorders with broader neurodegenerative involvement, supporting its potential role as a biomarker in selected, more complex HSP-related conditions. This evidence concerns the gene GFAP and hereditary spastic paraplegia.